Skip to content
CheckOrphan
  • Home
  • About Us
  • Log In
  • News
    • All News
    • Finance
    • Treatment
    • People
    • Research
  • Videos
  • Treatments
  • Clinical Trials
  • Access Programs
    • About Access Programs
  • Diseases
  • Events
  • Networks
  • Research
Main Menu

Subscribe for Free Newsletter

Email *

Type *

* Required Field
Email Marketing Services by Benchmark

Generate RSS

  1. Home
  2. /
  3. Treatment
  4. /
  5. Resiquimod

Resiquimod

April 13, 2017
Resiquimod
Trade Name
Orphan Indication Cutaneous T-cell lymphoma
EU Market Approval EU
EU Designation Date 2016-04-28 00:00:00
Sponsor Galderma R&D
Related Access Program
Seattle Genetics, Inc. – Lymphoma, T-Cell, Cutaneous

Related Treatment

  • Humanized IgG1 monoclonal antibody targeting KIR3DL2
  • Resiquimod
  • Chimeric locked nucleic acid deoxynucleoside phosphorothioate-linked o
  • Mogamulizumab
  • Fenretinide
More Treatment
pw

About CheckOrphan

CheckOrphan is a non-profit organization located in Basel, Switzerland and Santa Cruz, California that is dedicated to rare, orphan and neglected diseases. CheckOrphan offers users an interactive and dynamic platform for all these diseases. This strategy allows visitors to be updated daily on all the latest news and interact with people internationally. This is essential, because due to the nature of these diseases, there is not a large concentration of individuals within any given proximity.
Click here to know more About Us

Your email is important to us

Each email is sent to a CheckOrphan staff member and will be answered. We only use a contact form to avoid spam.

    Copyright © 2024 CheckOrphan.
    Developed by: Gonza.io logo Developed by: WebOptimalSolutions Powered by: Cloudscale logo